New approaches to the possible prevention of side effects of chemotherapy by nutrition Conference Paper


Authors: Pinto, J.; Raiczyk, G. B.; Huang, Y. P.; Rivlin, R. S.
Title: New approaches to the possible prevention of side effects of chemotherapy by nutrition
Conference Title: 2nd National Conference on Diet, Nutrition, and Cancer by the American Cancer Society
Abstract: In an effort to develop new methods for preventing side effects of chemotherapy, the authors initiated studies to determine whether Adriamycin (doxorubicin) inhibits the metabolism of riboflavin (vitamin B2). Adriamycin has been shown to form a 1:1 stoichiometric complex with riboflavin, as well as to compete for binding to tissue proteins. Adult rats treated with Adriamycin in clinically relevant doses were compared to control animals in ability to convert riboflavin into flavin adenine dinucleotide (FAD), the active flavin coenzyme derivative, in heart, skeletal muscle, liver, and kidney. Rats treated with Adriamycin exhibited diminished formation of carbon 14 (14C)FAD in skeletal muscle to nearly 50% that of controls, and in heart to about 70% to 80% of controls. Under these conditions, (14C)FAD formation in liver and kidney was largely unaffected by Adriamycin. In preliminary studies, riboflavin‐deficient animals treated with Adriamycin had accelerated mortality rates compared to those of food restricted controls treated with similar doses of Adriamycin. The data as a whole suggest a potential mechanism for Adriamycin‐induced cardiac and skeletal myopathy, i.e., inhibition of synthesis of FAD, a flavin coenzyme which is involved in electron transport, lipid metabolism, and energy generation. These findings in an animal model raise the possibility that defects of riboflavin nutriture, either dietary or drug‐induced, may be a determinant of Adriamycin toxicity. Further studies are required to explore the potential for preventing side effects due to Adriamycin by administration of this vitamin. Copyright © 1986 American Cancer Society
Keywords: cancer chemotherapy; doxorubicin; nonhuman; side effect; animal; animal experiment; animal model; liver; diet; kidney; cardiotoxicity; rat; muscle disease; rats; drug therapy; heart; adverse drug reaction; therapy; food deprivation; myocardium; flavin-adenine dinucleotide; muscle; muscles; drug interaction; nutrition; intoxication; vitamin metabolism; male; priority journal; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; myocardial diseases; riboflavin; riboflavin deficiency; flavine adenine nucleotide; flavine nucleotide; riboflavin c 14
Journal Title Cancer
Volume: 58
Issue: 8 Suppl.
Conference Dates: 1985 Sep 5-7
Conference Location: Houston, TX
ISBN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 1986-10-15
Start Page: 1911
End Page: 1914
Language: English
DOI: 10.1002/1097-0142(19861015)58:8+<1911::Aid-cncr2820581420>3.0.Co;2-1
PUBMED: 3756811
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 18 August 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. John   Pinto
    59 Pinto
  2. Richard S Rivlin
    67 Rivlin